Search Results
Jun 02, 2026, 09:00 ET Report: As Chief Legal Officers Face More Pressure, Pay Rises and External Hiring Increases
TCB.org l
More news about: The Conference Board
Jun 02, 2026, 08:59 ET Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥ 35% (SVR35)
More news about: Karyopharm Therapeutics Inc.
Jun 02, 2026, 08:24 ET Delta Debuts Prefabricated AI Modular Data Center Solution at COMPUTEX 2026 to Reduce Deployment Time by Up to 60%
indoor comfort.COMPUTEX 2026 will be held from June 2 to 5 at the Nangang Exhibition Center. Delta's booth is located in Hall 1, 4F, stand No. L0601a. We welcome media stakeholders, customers, partners and the general public to build the future of sustainable AI together with Delta.
More news about: Delta Electronics
Jun 02, 2026, 08:02 ET TalentLMS Introduces Learning Playground -- A Private Space for Employees to Practice Skills and Build Confidence
scale.TalentLMS gives learners AI-powered practice tools, including adaptive learning and AI coaching, to build real skills faster. It also gives managers and L&D teams the visibility to connect training directly to workforce capability. With self-directed practice, scoped reporting, and tighter integrations,
More news about: TalentLMS
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Jun 02, 2026, 07:20 ET Jersey Central Power & Light Company Announces Extension of Exchange Offer for its 4.150% Senior Notes due 2029, 4.400% Senior Notes due 2031 and 5.150% Senior Notes due 2036
which was declared effective on April 23, 2026.JCP&L serves 1.2 million customers in the counties of Burlington, Essex, Hunterdon, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Somerset, Sussex, Union and Warren. Follow JCP&L on X
More news about: Jersey Central Power & Light
Jun 02, 2026, 07:00 ET New High-grade Lithium, Caesium, and Tantalum Pegmatite Discoveries in Surface Exploration Works
("Overload") at the Pontax Property, with outcrop assay of 7.53% Cs2O and 3,768 ppm Ta2O5.Darren L. Smith, Executive Vice President Exploration for the Company, comments: "The recent surface exploration at Shaakichiuwaanaan has delivered multiple
More news about: PMET Resources Inc.
Jun 02, 2026, 06:45 ET SEM Stock Notification: Select Medical Board Investigated for Breaching its Duties to Investors Over $16.50 Acquisition Price
Strategic Finance and Operations; and Welsh, Carson, Anderson & Stowe ("WCAS"), a private equity company which has longstanding historical ties to Russel L. Carson, a director on Select Medical's board of directors.The merger will eliminate all holdings of Select Medical stock in exchange for $16.50
More news about: Bleichmar Fonti & Auld LLP
Jun 02, 2026, 04:39 ET Afreximbank Deepens Commitment to Economic Progress in The Bahamas
https://apo-opa.co/4o1IECADownload Image 2: https://apo-opa.co/3RFTcLy Caption - L-R: Honourable Michael B. Halkitis, Minister of Finance, The Bahamas, Mr. Okechukwu Ihejirika, Ag. Regional Chief Operating Officer, Afreximbank Caribbean
More news about: Afreximbank
Jun 02, 2026, 04:00 ET AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
https://doi.org/10.1186/s10194-022-01402-23 Al-Hassany L, Haas J, Piccininni M, et al. Sex and Gender Differences in Migraine. Front Neurol. 2020;11:549038.4 What is Migraine. The
More news about: AbbVie
Jun 02, 2026, 01:46 ET TOMY將推出首款配備Gravity Cannon的Ultrasaurus模型：ZOIDS「AZ-17DX ULTRA SAURUS GRAVITY CANNON Ver.」定於2027年2月下旬發售
https://cdn.kyodonewsprwire.jp/prwfile/release/M000076/202605259631/_prw_PI2fl_L6njKvK4.png開發者寄語：「為回應廣大ZOIDS動畫愛好者的期待，我們著手打造這款配備Gravity Cannon的Ultrasaurus模型。產品依靠齒輪傳動結構，完整還原從裝填到發射*的整套動作流程，兼顧運行穩定性與強勁動感。希望大家能喜愛這款在體型與配置上均創下系列新高的ZOIDS模型。」*模型可還原發射姿態，但炮彈不會實際射出。發售：2027年2月下旬
More news about: TOMY Company, Ltd.
Jun 02, 2026, 01:29 ET ASUS Adopts NVIDIA DSX AI Factory Platform to Accelerate Time to First Revenue
6 processor, including XA NR1I-E12L, an innovative hybrid-cooled option, and XA
More news about: ASUS
Jun 02, 2026, 01:11 ET ASUS Adopts NVIDIA DSX AI Factory Platform to Accelerate Time to First Revenue
6 processor, including XA NR1I-E12L, an innovative hybrid-cooled option, and XA
More news about: ASUS
Jun 02, 2026, 00:54 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
the patient achieved rapid and efficient hematopoietic reconstitution, with neutrophil engraftment observed on Day 13 and platelet counts exceeding 50×10^9/L on Day 21 post-treatment. Within one month after treatment, fetal hemoglobin (HbF) levels increased significantly and continuously, while sickle hemoglobin
More news about: CorrectSequence Therapeutics
Jun 02, 2026, 00:50 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
the patient achieved rapid and efficient hematopoietic reconstitution, with neutrophil engraftment observed on Day 13 and platelet counts exceeding 50×10^9/L on Day 21 post-treatment. Within one month after treatment, fetal hemoglobin (HbF) levels increased significantly and continuously, while sickle hemoglobin
More news about: CorrectSequence Therapeutics
Jun 01, 2026, 21:30 ET MSI presenteert vloeistofgekoelde AI-infrastructuur, NVIDIA MGX, NVIDIA DGX Station en DC-MHS-platformen op COMPUTEX 2026
21" 44OU ORv3-vloeistofgekoelde rekarchitectuur ondersteunt implementaties tot 100 kW met een geïntegreerde Liquid-to-Liquid Coolant Distribution Unit (L2L CDU, vloeistof-tot-vloeistof koelmiddeldistributieeenheid). Geconfigureerd met 28 x 1OU2N Open Compute multi-node-systemen, zorgt het bredere 21" ORv3-ontwerp
More news about: MSI
Jun 01, 2026, 21:30 ET MSI Showcases Liquid-Cooled AI Infrastructure, NVIDIA MGX, NVIDIA DGX Station and DC-MHS Platforms at COMPUTEX 2026
environments.The 21" 44OU ORv3 Liquid-Cooled Rack Architecture supports up to 100kW deployments with an integrated Liquid-to-Liquid Coolant Distribution Unit (L2L CDU). Configured with 28x 1OU2N Open Compute multi-node systems, the wider 21" ORv3 design enables higher compute density, efficient liquid cooling,
More news about: MSI
Jun 01, 2026, 21:30 ET MSI Showcases Liquid-Cooled AI Infrastructure, NVIDIA MGX, NVIDIA DGX Station and DC-MHS Platforms at COMPUTEX 2026
environments.The 21" 44OU ORv3 Liquid-Cooled Rack Architecture supports up to 100kW deployments with an integrated Liquid-to-Liquid Coolant Distribution Unit (L2L CDU). Configured with 28x 1OU2N Open Compute multi-node systems, the wider 21" ORv3 design enables higher compute density, efficient liquid cooling,
More news about: MSI
Jun 01, 2026, 21:30 ET MSI präsentiert auf der COMPUTEX 2026 flüssigkeitsgekühlte KI-Infrastruktur sowie die Plattformen NVIDIA MGX, NVIDIA DGX Station und DC-MHS
unterstützt Installationen mit einer Leistung von bis zu 100 kW und verfügt über eine integrierte Flüssigkeit-zu-Flüssigkeit-Kühlmittelverteilungseinheit (L2L CDU). Das breitere 21-Zoll-ORv3-Design, das mit 28 Open-Compute-Multi-Node-Systemen vom Typ 1OU2N konfiguriert ist, ermöglicht eine höhere Rechendichte,
More news about: MSI
Jun 01, 2026, 21:30 ET MSI présente l'infrastructure IA à refroidissement liquide, les plateformes NVIDIA MGX, NVIDIA DGX Station et DC-MHS au COMPUTEX 2026.
ORv3 21" à refroidissement par liquide prend en charge des déploiements jusqu'à 100 kW grâce à une unité de refroidissement liquide/liquide intégrée (L2L CDU). Configuré avec 28 systèmes multi-nœuds 1OU2N Open Compute, le design ORv3 21" plus large permet une plus grande densité de calcul, un refroidissement
More news about: MSI
Jun 01, 2026, 21:00 ET Peak Performance: Toyota Introduces the 2026 GRMN Corolla
EngineG16E-GTS 1.6L, 3-cylinder port injected turbo, 12-VALVE DOHC
More news about: Toyota Motor North America
Jun 01, 2026, 19:37 ET MemryX Appoints Ross Jatou as CEO and Joe Faris as VP of Sales and Marketing to Accelerate AI Infrastructure Expansion
moment for a leadership transition. Ross brings extensive executive experience in the global semiconductor space, spanning engineering leadership and P&L roles. MemryX has an exceptional engineering team and a strong fundamental architecture, and I'm confident Ross is well positioned to lead the company
More news about: MemryX
Jun 01, 2026, 18:58 ET CoolIT Systems Demonstrates 15kW Coldplate, Extending Single-Phase DLC Roadmap Far Beyond 2030
2025.The 15kW coldplate uses CoolIT's Split-Flow™ microchannel architecture and was validated with a standard water-glycol coolant at 1.2 L/min/kW, with system-level thermal performance suitable for 45°C warm-water cooling environments."AI accelerator innovation depends on cooling architectures
More news about: CoolIT Systems Inc
Jun 01, 2026, 17:08 ET MemryX Appoints Ross Jatou as CEO and Joe Faris as VP of Sales and Marketing to Accelerate AI Infrastructure Expansion
moment for a leadership transition. Ross brings extensive executive experience in the global semiconductor space, spanning engineering leadership and P&L roles. MemryX has an exceptional engineering team and a strong fundamental architecture, and I'm confident Ross is well positioned to lead the company
More news about: MemryX
Jun 01, 2026, 16:05 ET Cirius Therapeutics Announces Presentation on CIR-0602K as Novel Diabetes Treatment at the American Diabetes Association's 2026 Scientific Sessions
Options to Manage Diabetes [Board No. 1794]Authors: M. Abu-Farha, I. Al Khairi, J.A. Abubaker, R.A. DeFronzo, M. Abdul-Ghani, L. Norton, J.R. Colca, F. Al-Mulla, K.S. McCommisDate & Time: Sunday, June 7, at 12:30 AM CT (poster will be up throughout
More news about: Cirius Therapeutics